Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects

详细信息    查看全文

• 作者：Yun Xue ; Jeffrey M. Cohen ; Natalie A. Wright…
• 刊名：American Journal of Clinical Dermatology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：17
• 期：2
• 页码：147-162
• 全文大小：828 KB
• 参考文献：1.Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;5:907–27.CrossRef
  2.Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMed CrossRef
  3.Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722–7.PubMed PubMedCentral CrossRef
  4.Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in olmsted county, Minnesota, in 1995–2007 versus 1985–1994: a population-based study. J Rheumatol. 2011;38:983–9.PubMed PubMedCentral CrossRef
  5.Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology. 1999;38:668–74.PubMed CrossRef
  6.Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61:335–40.PubMed PubMedCentral CrossRef
  7.Turesson C, Jacobsson LTH, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:59–64.PubMed PubMedCentral CrossRef
  8.Magro CM, Crowson AN. The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol. 2003;30:1–10.PubMed CrossRef
  9.Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol. 2005;53:191–209.PubMed CrossRef
  10.Yamamoto T. Cutaneous manifestations associated with rheumatoid arthritis. Rheumatol Int. 2009;29:979–88.PubMed CrossRef
  11.Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.PubMed PubMedCentral CrossRef
  12.Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015. doi:10.​1136/​annrheumdis-2015-207524 .
  13.Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094–108.PubMed CrossRef
  14.Klarenbeek NB, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Recent advances in the management of rheumatoid arthritis. BMJ. 2010;341:c6942.PubMed CrossRef
  15.Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011;84:1245–52.PubMed
  16.García-Patos V. Rheumatoid nodule. Semin Cutan Med Surg. 2007;26:100–7.PubMed CrossRef
  17.Kaye BR, Kaye RL, Bobrove A. Rheumatoid nodules. Review of the spectrum of associated conditions and proposal of a new classification, with a report of four seronegative cases. Am J Med. 1984;76:279–92.PubMed CrossRef
  18.Turesson C, Jacobsson LTH. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33:65–72.PubMed CrossRef
  19.Nyhäll-Wåhlin B-M, Turesson C, Jacobsson LTH, Nilsson J-Å, Forslind K, Albertsson K, et al. The presence of rheumatoid nodules at early rheumatoid arthritis diagnosis is a sign of extra-articular disease and predicts radiographic progression of joint destruction over 5 years. Scand J Rheumatol. 2011;40:81–7.PubMed CrossRef
  20.Nyhäll-Wåhlin B-M, Jacobsson LTH, Petersson IF, Turesson C. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis. 2006;65:601–6.PubMed PubMedCentral CrossRef
  21.Turesson C, McClelland R, Christianson T, Matteson EL. Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol. 2008;35:179.PubMed
  22.McGrath MH, Fleischer A. The subcutaneous rheumatoid nodule. Hand Clin. 1989;5:127–35.PubMed
  23.Rozin A, Yigla M, Guralnik L, Keidar Z, Vlodavsky E, Rozenbaum M, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol. 2006;25:384–8.PubMed CrossRef
  24.Baan H, Haagsma CJ, van de Laar MAFJ. Corticosteroid injections reduce size of rheumatoid nodules. Clin Rheumatol. 2006;25:21–3.PubMed CrossRef
  25.Ching DW, Petrie JP, Klemp P, Jones JG. Injection therapy of superficial rheumatoid nodules. Br J Rheumatol. 1992;31:775–7.PubMed CrossRef
  26.Bywaters EG, Scott JT. The natural history of vascular lesions in rheumatoid arthritis. J Chronic Dis. 1963;16:905–14.PubMed CrossRef
  27.Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60:288–97.CrossRef
  28.Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 2014;53:890–9.CrossRef
  29.Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case–control study. Ann Rheum Dis. 1996;55:190–2.PubMed PubMedCentral CrossRef
  30.Vollertsen RS, Conn DL. Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am. 1990;16:445–61.PubMed
  31.Watts RA, Carruthers DM, Scott DG. Isolated nail fold vasculitis in rheumatoid arthritis. Ann Rheum Dis. 1995;54:927–9.PubMed PubMedCentral CrossRef
  32.Katz SI, Gallin JI, Hertz KC, Fauci AS, Lawley TJ. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore). 1977;56:443–55.PubMed CrossRef
  33.Tuveri M, Generini S, Matucci-Cerinic M, Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet (London, England). 2000;356:1739–40.CrossRef
  34.Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides. Medicine (Baltimore). 2005;84:115–28.PubMed CrossRef
  35.Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol. 2006;24:414–29.PubMed CrossRef
  36.Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48:311–40.PubMed CrossRef
  37.Hellmann M, Jung N, Owczarczyk K, Hallek M, Rubbert A. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:929–30.CrossRef
  38.Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol. 2010;28:81–3.PubMed
  39.Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med. 1991;151:2249–54.PubMed CrossRef
  40.Puéchal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken). 2012;64:331–9.CrossRef
  41.Benucci M, Li Gobbi F, Saviola G, Manfredi M. Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab). Rheumatol Int. 2008;28:1253–5.PubMed CrossRef
  42.Van Der Bijl AE, Allaart CF, Van Vugt JPP, Van Duinen SG, Breedveld FC. Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005;32:1607–9.PubMed
  43.Callen JP. Neutrophilic dermatoses. Dermatol Clin. 2002;20:409–19.PubMed CrossRef
  44.Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 2009;10:301–12.PubMed CrossRef
  45.von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31:535–56 (quiz 557–60).PubMed CrossRef
  46.Cohen PR, Holder WR, Rapini RP. Concurrent Sweet’s syndrome and erythema nodosum: a report, world literature review and mechanism of pathogenesis. J Rheumatol. 1992;19:814–20.PubMed
  47.Cohen PR. Sweet’s syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.PubMed PubMedCentral CrossRef
  48.Cohen PR, Kurzrock R. Sweet’ s syndrome a review of current treatment options. Am J Clin Dermatol. 2002;3:117–31.PubMed CrossRef
  49.Cohen PR, Holder WR, Tucker SB, Kono S, Kurzrock R. Sweet syndrome in patients with solid tumors. Cancer. 1993;72:2723–31.PubMed CrossRef
  50.Maillard H, Leclech C, Peria P, Avenel-Audran M, Verret JL. Colchicine for Sweet’s syndrome. A study of 20 cases. Br J Dermatol. 1999;140:565–6.PubMed CrossRef
  51.Suehisa S, Tagami H. Treatment of acute febrile neutrophilic dermatosis (Sweet’s syndrome) with colchicine. Br J Dermatol. 1981;105:483.PubMed CrossRef
  52.Horio T, Danno K, Okamoto H, Miyachi Y, Imamura S. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol. 1983;9:77–81.PubMed CrossRef
  53.el Sherif AI, Bharija SC, Belhaj MS, Singh G. Dapsone in Sweet syndrome. Int J Dermatol. 1990;29:737.
  54.Schwaegerle SM, Bergfeld WF, Senitzer D, Tidrick RT. Pyoderma gangrenosum: a review. J Am Acad Dermatol. 1988;18:559–68.PubMed CrossRef
  55.Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646–54.PubMed CrossRef
  56.Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am. 2007;33:787–802 (vi).PubMed CrossRef
  57.Harris AJ, Regan P, Burge S. Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement. BMJ. 1998;316:52–3.PubMed PubMedCentral CrossRef
  58.Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13:191–211.PubMed CrossRef
  59.Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273–83.PubMed CrossRef
  60.Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059–61.PubMed CrossRef
  61.Brooklyn TN, Dunnill MGS, Shetty A, Bowden JJ, Williams JDL, Griffiths CEM, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9.PubMed PubMedCentral CrossRef
  62.Kreuter A, Reich-Schupke S, Stücker M, Altmeyer P, Gambichler T. Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol. 2008;158:856–7.PubMed CrossRef
  63.Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol. 2007;157:1235–9.PubMed CrossRef
  64.Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol. 2008;33:229–33.PubMed CrossRef
  65.Düker I, Schaller J, Rose C, Zillikens D, Hashimoto T, Kunze J. Subcorneal pustular dermatosis-type IgA pemphigus with autoantibodies to desmocollins 1, 2, and 3. Arch Dermatol. 2009;145:1159–62.PubMed CrossRef
  66.Sangueza OP, Caudell MD, Mengesha YM, Davis LS, Barnes CJ, Griffin JE, et al. Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol. 2002;47:251–7.PubMed CrossRef
  67.Gulati A, Paige D, Yaqoob M, Proby CM, Cerio R, Harwood CA. Palisaded neutrophilic granulomatous dermatitis associated with systemic lupus erythematosus presenting with the burning rope sign. J Am Acad Dermatol. 2009;61:711–4.PubMed CrossRef
  68.Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol. 1994;130:1278–83.PubMed CrossRef
  69.Martin JA, Jarrett P. Rheumatoid papules treated with dapsone. Clin Exp Dermatol. 2004;29:387–9.PubMed CrossRef
  70.Long D, Thiboutot DM, Majeski JT, Vasily DB, Helm KF. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol. 1996;34:957–61.PubMed CrossRef
  71.Verneuil L, Dompmartin A, Comoz F, Pasquier CJ, Leroy D. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies. J Am Acad Dermatol. 2001;45:286–91.PubMed CrossRef
  72.Perrin C, Lacour JP, Castanet J, Michiels JF. Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol. 2001;23:295–8.PubMed CrossRef
  73.Ackerman AB, Guo Y, Vitale P, et al. Clues to diagnosis in dermopathology. Chicago: ASCB Press; 1993.
  74.Altaykan A, Erkin G, Boztepe G, Gököz A. Interstitial granulomatous dermatitis with arthritis. Hum Pathol. 2004;35:892–4.PubMed CrossRef
  75.Ahmed ZS, Joad S, Singh M, Bandagi SS. Interstitial granulomatous dermatitis successfully treated with etanercept. Am J Case Rep. 2014;15:94–6.PubMed PubMedCentral CrossRef
  76.Zoli A, Massi G, Pinnelli M, Lo Cuccio CDB, Castri F, Ferraccioli G. Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. Clin Rheumatol. 2010;29:99–101.PubMed CrossRef
  77.Rosenstein ED, Kramer N. Felty’s and pseudo-Felty’s syndromes. Semin Arthritis Rheum. 1991;21:129–42.PubMed CrossRef
  78.Balint GP, Balint PV. Felty’s syndrome. Best Pract Res Clin Rheumatol. 2004;18:631–45.PubMed CrossRef
  79.Lard LR, Visser H, Speyer I, Vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446–51.PubMed CrossRef
  80.van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996;124:699–707.PubMed CrossRef
  81.Broggini M, Baratelli E, Cappelli A, Crespi E, Filardi PG, Volontè S. Cutaneous side effects induced by d -penicillamine in the treatment of rheumatoid arthritis. Minerva Med. 1990;81:197–201.PubMed
  82.Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61:104–11.PubMed CrossRef
  83.Lage D, Juliano PB, Metze K, de Souza EM, Cintra ML. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol. 2012;51:1199–205.PubMed CrossRef
  84.Shimizu C, Hanakawa H, Ohtsuki N. Lichenoid drug eruption. Nishinihon J Dermatol. 1998;60:494–7.CrossRef
  85.Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 1993;29:249–55.PubMed CrossRef
  86.Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica. 1989;179:10–3.PubMed CrossRef
  87.Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol. 1998;16:325–32.PubMed CrossRef
  88.Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol. 1998;134:1521–30.PubMed
  89.Laurberg G, Geiger JM, Hjorth N, Holm P, Hou-Jensen K, Jacobsen KU, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol. 1991;24:434–7.PubMed CrossRef
  90.Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29:822–31.PubMed CrossRef
  91.Ahern M, Lever JV, Cosh J. Complete heart block in rheumatoid arthritis. Ann Rheum Dis. 1983;42:389–97.PubMed PubMedCentral CrossRef
  92.Agarwal V, Aggarwal A, Misra R. Methotrexate induced accelerated nodulosis. J Assoc Physicians India. 2004;52:538–40.PubMed
  93.Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy. 2002;22:1157–62.PubMed CrossRef
  94.Williams FM, Cohen PR, Arnett FC. Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. J Am Acad Dermatol. 1998;39:359–62.PubMed CrossRef
  95.Kerstens PJ, Boerbooms AM, Jeurissen ME, Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol. 1992;19:867–71.PubMed
  96.Merrill JT, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1997;40:1308–15.PubMed
  97.Abraham Z, Rozenbaum M, Rosner I. Colchicine therapy for low-dose-methotrexate-induced accelerated nodulosis in a rheumatoid arthritis patient. J Dermatol. 1999;26:691–4.PubMed CrossRef
  98.Combe B, Didry C, Gutierrez M, Anaya JM, Sany J. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med. 1993;2:153–6.PubMed
  99.Dash S, Seibold JR, Tiku ML. Successful treatment of methotrexate induced nodulosis with d -penicillamine. J Rheumatol. 1999;26:1396–9.PubMed
  100.Moustou A-E, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486–504.PubMed CrossRef
  101.Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12.PubMed CrossRef
  102.González-López MA, Martínez-Taboada VM, González-Vela MC, Blanco R, Fernández-Llaca H, Rodríguez-Valverde V, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol. 2007;32:672–4.PubMed CrossRef
  103.van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PLCM, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62:1168–77.PubMed PubMedCentral CrossRef
  104.Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–5.PubMed CrossRef
  105.Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs. 2004;64:1767–77.PubMed CrossRef
  106.Lequerré T, Vittecoq O, Klemmer N, Goëb V, Pouplin S, Menard JF, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol. 2006;33:1307–14.PubMed
  107.Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–24.PubMed CrossRef
  108.Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006;8:R131.PubMed PubMedCentral CrossRef
  109.Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–51.PubMed CrossRef
  110.Mohan N, Edwards ET, Cupps TR, Slifman N, Lee J-H, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955–8.PubMed
  111.Duffy TN, Genta M, Moll S, Martin P-Y, Gabay C. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:S106.PubMed
  112.Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G. Henoch-Schönlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol. 2006;12:249–51.PubMed CrossRef
  113.Rahman FZ, Takhar GK, Roy O, Shepherd A, Bloom SL, McCartney SA. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn’s disease. World J Gastrointest Pharmacol Ther. 2010;1:119–22.PubMed PubMedCentral CrossRef
  114.Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohn’s Colitis. 2014;8:480–8.CrossRef
  115.Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209–15.PubMed PubMedCentral CrossRef
  116.Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14.PubMed CrossRef
  117.Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001.PubMed CrossRef
  118.Palmou-Fontana N, Sanchez Gavino JA, McGonagle D, Garcia-Martinez E, Iniguez de Onzono Martin L. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology. 2014;228:311–3.CrossRef
  119.Brunasso A, Massone C. Plantar pustulosis during rituximab therapy for rheumatoid arthritis. J Am Acad Dermatol. 2012;67:e148–50.PubMed CrossRef
  120.Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–8.PubMed CrossRef
  121.Flendrie M, Vissers WHPM, Creemers MCW, de Jong EMGJ, van de Kerkhof PCM, van Riel PLCM. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666–76.PubMed PubMedCentral CrossRef
  122.Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology. 2006;213:182–6.PubMed CrossRef
  123.Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007;34:468–72.PubMed CrossRef
  124.Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis. 2007;80:231–7.PubMed
  125.Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.PubMed CrossRef
  126.Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev. 2012;11:321–5.PubMed CrossRef
  127.Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus. 2009;18:690–7.PubMed CrossRef
  128.Varada S, Gottlieb AB, Merola JF, Saraiya AR, Tintle SJ. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol. 2015;72:253–60.PubMed CrossRef
  129.Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology. 2009;48:1451–4.PubMed CrossRef
  130.De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545–51.PubMed PubMedCentral CrossRef
  131.Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165:335–41.PubMed CrossRef
  132.Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19:1107–11.PubMed CrossRef
  133.Stratigos AJ, Antoniou C, Stamathioudaki S, Avgerinou G, Tsega A, Katsambas AD. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150–3.PubMed CrossRef
  134.Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002;146:334–5.PubMed CrossRef
  135.Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011;50:619–25.PubMed CrossRef
  136.Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716–20.CrossRef
  137.Brunasso AMG, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. Sci World J. 2014;2014:179180.CrossRef
  138.Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780–4.PubMed PubMedCentral
  139.Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol. 2004;18:429–62.PubMed CrossRef
  140.Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K, Yoneda K, et al. Development of sarcoidosis during etanercept therapy. Intern Med. 2008;47:1021–5.PubMed CrossRef
  141.Bremner R, Simpson E, White CR, Morrison L, Deodhar A. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum. 2004;34:610–6.PubMed CrossRef
  142.Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142:198–202.PubMed
  143.Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67:567–70.PubMed CrossRef
  144.Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953–6.PubMed CrossRef
  145.Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005;141:861–4.PubMed
  146.Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.PubMed CrossRef
  147.Raaschou P, Simard JF, Holmqvist M, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939.PubMed CrossRef
  148.Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc J-L, et al. Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One. 2012;7:e48991.PubMed PubMedCentral CrossRef
  149.Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Risk of malignancy including non-melanoma skin cancers with anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol. 2012;30:756–64.PubMed
  150.Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–45.PubMed CrossRef
  151.Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology. 2008;47:698–701.PubMed CrossRef
  152.Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119–30.PubMed CrossRef
  
• 作者单位：Yun Xue (1)
  Jeffrey M. Cohen (2)
  Natalie A. Wright (1)
  Joseph F. Merola (1) (3)
  
  1. Department of Dermatology, Brigham and Women’s Hospital and Harvard Medical School, 41 Avenue Louis Pasteur, Suite 319, Boston, MA, 02115, USA
  2. Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
  3. Division of Rheumatology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
  
• 刊物主题：Dermatology; Pharmacotherapy; Pharmacology/Toxicology;
• 出版者：Springer International Publishing
• ISSN：1179-1888

文摘

Rheumatoid arthritis (RA) is a systemic inflammatory disorder that primarily affects the joints, but may exhibit extra-articular, including cutaneous, manifestations such as rheumatoid nodules, rheumatoid vasculitis, granulomatous skin disorders, and neutrophilic dermatoses. A large burden of cutaneous disease may be an indication of RA disease activity and the need for more aggressive treatment. Many of the therapeutic agents used to treat RA can also result in cutaneous adverse effects, which pose their own diagnostic and therapeutic challenges. Anti-TNFα agents, in particular, have a wide variety of adverse effects including psoraisiform eruptions, granulomatous conditions, and cutaneous connective tissue disorders. Herein we provide an update on the clinical presentations and management of RA-associated cutaneous findings as well as drug-induced cutaneous effects, with particular attention to the adverse effects of biologic disease-modifying agents.